MedTrace Logo

Novel Therapeutic Approach for Human T-cell Malignancies

NCT06600568 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2026-08-06

No results posted yet for this study

Summary

This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.

Interactions between drugs capable of activating the apoptotic process (e.g., Venetoclax) and drugs capable of altering ROS homeostasis (e.g., inhibitors of the enzyme glucose-6-phosphate dehydrogenase) will be examined.

The most promising compounds will be selected based on results obtained in vitro on cell lines and PDX already available in the laboratory, and then will be assayed ex vivo in cells obtained from patients with resistant/refractory T-cell neoplasms.

Conditions

  • T-Cell Leukemia/Lymphoma, Adult

Interventions

OTHER

Translation analysis

Novel strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.

Sponsors & Collaborators

  • Istituto Nazionale Tumori IRCSS-Fondazione G.Pascale

    collaborator UNKNOWN

  • Istituto Oncologico Veneto IRCCS

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-18
Primary Completion
2027-03-01
Completion
2027-03-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06600568 on ClinicalTrials.gov